[Cu(DDC)2] NP treatment with significantly upregulated the Granzyme B expression (Figure 3I), a key marker of T cell activation and immune-mediated tumor cell killing, suggesting enhanced cytotoxic T lymphocyte (CTL) activity within the tumor microenvironment. The gene discussed is GZMB; the disease is neoplasm.